# Caffeine Citrate

## Peyona inj 20mg/1mL \(for infusion and oral\)

| 藥物代碼 | IPEY |
| :--- | :--- |
| 適應症 | Treatment of primary apnoea of premature newborns. |
| 副作用 | Cardiovascular: Angina pectoris, chest pain, flushing, palpitations, sinus tachycardia, supraventricular tachycardia, vasodilatation, ventricular arrhythmiaCentral nervous system: Agitation, delirium, dizziness, hallucination, headache, insomnia, irritability, psychosis, restlessnessDermatologic: Urticaria Gastrointestinal: Esophageal motility disorder \(sphincter tone decreased\), gastritisGenitourinary: DiuresisNeuromuscular & skeletal: Fasciculations Ophthalmic: Increased intraocular pressure \(&gt;180 mg caffeine\), miosis |
| 禁忌 | Hypersensitivity to the active substance or to any of the excipients. |
| 藥物保存方式 | 室溫 |
| 用法用量 | Each 1 mL ampoule contains 20 mg caffeine citrate \(equivalent to 10 mg caffeine\) Apnea of prematurity: Neonates:Loading dose: Minimum dose: 20 mg/kg as caffeine citrate, Intravenous infusion over 30 minutes, a second loading dose of 10 -20 mg/kg maximum may be given after 24 hours; Maintenance dose: 5 mg/kg/day as caffeine citrate once daily starting 24 hours after the loading dose, Intravenous infusion \(over 10 minutes\) or by oral administration.Oral: May be administered without regard to feedings or meals. |
| 肝功能異常 | 無需調整劑量  has not been studied |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 尚未確立 |
| 孕期用藥建議 | N/A |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | Unknown 尚未建立 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | AC, AC15, IVD, PC, PO |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | 【D5W】 可選 仿單建議  【N/S】 可選 仿單建議 |
| IVP 用法建議 | X |
| IVD 用法建議 | Infuse loading dose 20 mg/kg as caffeine citrate may be infused over at least 30 minutes; maintenance dose 5 mg/kg/day as caffeine citrate once daily may be infused over at least 10 minutes. |
| 注意事項 | 1.Caffeine citrate can be either used without dilution or diluted in sterile solutions for infusion such as glucose 50 mg/mL \(5%\) or sodium chloride 9 mg/mL \(0.9%\) or calcium gluconate 100 mg/mL \(10%\) immediately after withdrawal from the ampoule. 2.Blood samples for monitoring should be taken just before the next dose in the case of therapeutic failure and 2 to 4 hours after the previous dose when suspecting toxicity. |

